Pay in 4 interest-free payments of $18.75 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Pro-apoptotic effect of ZT-12-037-01 is dramatically enhanced in cells expressing oncogenic NRAS
Chronic treatment of db/db mice with Roflumilast N-oxide at 3 mg/kg shows prevention of disease progression
Formula: C20H24N4O4
Indiplon: a nonbenzodiazepine sedative-hypnotic for the treatment of insomnia
Canagliflozin - CAS# 842133-18-0 Catalog No.:M10730-10 Pro-apoptotic effect of ZT-12-037-01 isCanagliflozin (INN, trade name Invokana) is a drug for the treatment of type 2 diabetes. It was developed by Mitsubishi Tanabe Pharma and is marketed under license by Janssen, a division of Johnson & Johnson. Canagliflozin is an inhibitor of subtype 2 sodium glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the